9S
9SO.F Solasia Pharma K.K
- Market cap
- EUR 31.7M
- P/E
- -
- P/B
- 3.86x
- ROE
- -79.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 9SO.F undervalued?
Graham numberThe Graham number of Solasia Pharma K.K cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Solasia Pharma K.K fundamental analysis
No fundamental analysis for Solasia Pharma K.K yet.
Solasia Pharma K.K stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Solasia Pharma K.K
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherap…
Full company profileSolasia Pharma K.K financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Solasia Pharma K.K annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 501M | 411M | 318M | 1.31B | 454M | 559M | 1.09B | 617M | 316M | 429M | 16.0M |
| Gross Profit | 501M | 411M | 105M | 1.24B | 244M | 373M | 662M | 337M | 185M | 207M | 12.0M |
| Operating Income | -462M | -1.01B | -2.42B | -1.76B | -4.12B | -2.42B | -2.47B | -1.14B | -1.95B | -860M | -1.14B |
| EBITDA | - | -1.01B | -2.27B | -1.29B | -3.62B | -1.92B | -1.94B | -635M | -1.76B | -862M | -1.10B |
| Net Income | -474M | -1.01B | -2.42B | -1.87B | -4.13B | -2.48B | -2.55B | -1.11B | -1.94B | -876M | -1.16B |
| EPS | - | -11 | -23 | -16 | -34 | -19 | -15 | -6.39 | -8.90 | -3.33 | -4.24 |
| Balance Sheet | |||||||||||
| Total Assets | 3.70B | 6.66B | 7.73B | 7.95B | 5.78B | 3.14B | 3.13B | 2.23B | 1.36B | 2.08B | 1.90B |
| Total Liabilities | 272M | 447M | 641M | 1.03B | 2.12B | 557M | 472M | 354M | 206M | 458M | 445M |
| Shareholders' Equity | 3.43B | 6.21B | 7.09B | 6.92B | 3.65B | 2.59B | 2.66B | 1.87B | 1.16B | 1.62B | 1.45B |
| Cash & Short-term Investments | 1.04B | 3.37B | 4.05B | 4.12B | 2.96B | 714M | 803M | 728M | 886M | 1.38B | 1.29B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -464M | -911M | -2.32B | -828M | -2.79B | -2.47B | -2.07B | -1.24B | -1.03B | - | -650M |
| Capital Expenditure | 558M | 52.0M | 52.0M | 2.00M | 10.0M | 2.00M | 403M | 0.00 | 1.00M | 0.00 | 0.00 |
| Free Cash Flow | - | -1.41B | -2.58B | -1.56B | -2.96B | -2.64B | -2.48B | -1.24B | -1.03B | - | -650M |
| Ratios | |||||||||||
| ROE | -13.8% | -16.2% | -34.2% | -27.0% | -113.0% | -95.8% | -95.7% | -59.3% | -167.8% | -54.1% | -79.7% |
| ROA | -12.8% | -15.1% | -31.3% | -23.5% | -71.5% | -78.8% | -81.3% | -49.9% | -142.5% | -42.2% | -61.0% |
| Net Profit Margin | -94.6% | -245.2% | -761.6% | -142.5% | -909.0% | -443.3% | -233.3% | -180.2% | -614.2% | -204.2% | -7,237.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Solasia Pharma K.K dividends
Solasia Pharma K.K has not paid dividends in the last 9 fiscal years.
Who owns Solasia Pharma K.K
- Insiders 14.62%
- Institutions 1.25%
- Public & others 84.13%
- Shares outstanding 273M
- Free float 237M
Solasia Pharma K.K company profile
- Company name
- Solasia Pharma K.K
- Ticker
- 9SO.F
- ISIN
- JP3436500007
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 22
- Fiscal year end
- December
- Address
- Sumitomo Fudosan Shiba-Koen Tower, Minato, Japan, 105-0011
- Phone
- 81 3 5843 8046
- Website
- solasia.co.jp
About Solasia Pharma K.K
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
Solasia Pharma K.K management
7- Mr. Yoshihiro AraiPresident, CEO & Representative Director · born 1960
- Mr. Toshio MiyashitaCFO, Head of Administration & Director · born 1967
- Yasumitsu ShimadaAccounting Manager
- Yasuaki ManabeHead of Marketing Division
- Fumiko NagahamaHead of Product Development Division
- Wataru KobayashiHead of Reliability Assurance Division
- Kozo YaoHead of Business Development